Xenon Pharmaceuticals Inc (XENE)

NASDAQ
18.05
-0.12(-0.66%)
  • Volume:
    247,663
  • Bid/Ask:
    17.50/24.98
  • Day's Range:
    17.55 - 18.14

XENE Overview

Prev. Close
18.17
Day's Range
17.55-18.14
Revenue
29.44M
Open
18.01
52 wk Range
9.32-21.91
EPS
-1.01
Volume
247,663
Market Cap
739.46M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
148,682
P/E Ratio
-
Beta
1.43
1-Year Change
39.49%
Shares Outstanding
40,967,221
Next Earnings Date
Aug 10, 2021
What is your sentiment on Xenon Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Xenon Pharmaceuticals Inc News

Xenon Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyNeutralSellBuy
Technical IndicatorsStrong BuyStrong BuyBuyStrong SellStrong Buy
SummaryStrong BuyStrong BuyNeutralStrong SellStrong Buy

Xenon Pharmaceuticals Inc Company Profile

Xenon Pharmaceuticals Inc Company Profile

Employees
126

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company’s product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop FX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.